Find Funding Opportunities

The purpose of this notice is to extend the response date for NOT-NS-22-073 "Request for Information (RFI) on Advancing Research in Fundamental Neuroscience".

The purpose of this notice is to cancel the July 7, 2022 receipt date for this FOA. The October 1, 2022 will remain unchanged.

The National Institute on Drug Abuse (NIDA) intends to solicit proposals from qualified organizations (NAICS Code 541715) having in-house capability to support and provide resources to the participating grantees for completing biocompatibility studies, in vivo animal testing compliant with good laboratory (GLP) guidelines, and sterilization and shelf-life testing. This contractor will provide support for research protocol development, research staff training, and conduct all testing necessary to support biocompatibility, sterilization, and animal safety studies.

The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in research to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating tools including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics.

The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in hypothesis-driven research projects that focus on deciphering the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus and to examine new approaches for treatment.

This Notice is a Request for Information (RFI) on approaches NIH can take to promote greater equity in global health research, particularly research that engages scientists in low and middle-income countries (LMICs) (REF).

The purpose of this notice is to inform applicants of a change to the Key Dates for PAR-20-111 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)". An additional receipt date has been added to this FOA.

The purpose of this notice is to inform applicants of a change to the Key Dates for PAR-20-122 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)". An additional receipt date has been added to this FOA.

The purpose of this notice is to correct an error in PAR-21-056 which incorrectly states that "Foreign components, as defined in the NIH Grants Policy Statement, are not allowed." As this should be corrected to reflect that Foreign components are allowed. This aligns with the companion PARs which all allow foreign components.

The purpose of this notice is to inform the community of the early termination of RFA-NS-21-015 "HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)" and it's reissuance as RFA-NS-22-052